- Home
- DXR vs OFS Comparison
DXR vs OFS Comparison
Compare DXR & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$10.53
Company Overview
Basic Information| Metric | DXR | OFS |
|---|---|---|
| Founded | 1970 | 2001 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Medical/Dental Instruments | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 54.3M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | DXR | OFS |
|---|---|---|
| Price | $10.53 | $3.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.2K | ★ 73.2K |
| Earning Date | 02-27-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 16.83% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,446,345.00 | N/A |
| Revenue This Year | $44,935.22 | N/A |
| Revenue Next Year | $74.79 | N/A |
| P/E Ratio | $33.83 | ★ $17.44 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.56 | $2.72 |
| 52 Week High | $14.76 | $8.99 |
Technical Indicators
Market Signals| Indicator | DXR | OFS |
|---|---|---|
| Relative Strength Index (RSI) | 54.03 | 54.66 |
| Support Level | $9.64 | $3.29 |
| Resistance Level | $10.65 | $4.11 |
| Average True Range (ATR) | 0.34 | 0.17 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 64.78 | 67.63 |
Price Performance
Historical Comparison DXR
OFS
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
About OFS OFS Capital Corporation
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.